Headlines
Swiss ministers meet with pharma executives amid tariff uncertainty
Published by Global Banking & Finance Review®
Posted on August 14, 2025
2 min readLast updated: January 22, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on August 14, 2025
2 min readLast updated: January 22, 2026
Swiss ministers met with Roche and Novartis to discuss US tariff impacts on pharmaceuticals, with further talks planned for September.
ZURICH (Reuters) -Swiss ministers have met with senior executives of pharmaceutical companies Roche and Novartis to discuss the outlook for the sector under current U.S. trade policy, the government said on Thursday.
President Donald Trump has imposed U.S. import tariffs of 39% on Swiss goods, one of the highest rates worldwide, though pharmaceutical firms have so far been spared the duties.
The Trump administration is carrying out a probe into pharmaceutical imports, after which tariffs could follow.
Swiss Interior Minister Elisabeth Baume-Schneider and Economy Minister Guy Parmelin met on Thursday morning with Roche Chairman Severin Schwan and Patrick Horber, head of the international unit for Novartis, the government said.
"The participants of the meeting exchanged their views on the current situation in the pharmaceutical industry against the backdrop of discussions about the tariffs imposed by the United States," the Interior Ministry said in a statement.
What was discussed is confidential, the ministry said, noting that the ministers were organising a roundtable discussion with the pharmaceutical industry in September.
(Writing by Dave Graham. Additional reporting by Ariane Luthi. Editing by Mark Potter)
U.S. tariffs are taxes imposed on imported goods, which can affect trade relationships and pricing for consumers and businesses.
Trade policy refers to the laws and regulations that a country establishes to manage its international trade, including tariffs and import/export restrictions.
Explore more articles in the Headlines category
